MENA MedTech Insights cover art

MENA MedTech Insights

MENA MedTech Insights

By: Ran Chen
Listen for free

About this listen

 Welcome to MENA MedTech Insights, the definitive podcast for professionals in the Middle East and North Africa's rapidly growing medical technology sector. Each episode, we explore the latest innovations, market trends, and regulatory landscapes, featuring exclusive interviews with the founders, investors, and leaders who are shaping the future of healthcare in the region.Copyright 2026 Ran Chen Biological Sciences Economics Science
Episodes
  • Riyadh's New Playbook: Decoding SFDA's AI Rules with Pure Global

    Riyadh's New Playbook: Decoding SFDA's AI Rules with Pure Global
    Apr 1 2026
    Last week, the CEO of the Saudi Food and Drug Authority (SFDA) announced a strategic push to integrate Artificial Intelligence into its own regulatory frameworks. This move is set to redefine the standards for MedTech approvals in the Kingdom, creating a more sophisticated and demanding environment for innovators. This episode explores what an AI-powered regulator means for companies and how it changes the rules for market access. While this initiative promises to streamline processes, it also raises the bar for submission quality. An AI-powered regulator will have unprecedented capabilities to scrutinize clinical data, validate algorithms, and monitor devices post-market. This presents a new challenge for companies accustomed to traditional regulatory pathways. Are you prepared for a regulator that understands your technology as well as you do? Key Takeaways: - What specific changes can MedTech companies expect from an AI-powered SFDA review process? - How does the SFDA's new focus impact data requirements for AI and machine learning devices? - What are the new risks of an incomplete or non-transparent submission in this environment? - Why is post-market surveillance for AI software more critical under this new framework? - How should companies adapt their regulatory strategy to align with Saudi Vision 2030? - What does this shift signal for other regulatory bodies across the MENA region? - How do you demonstrate algorithmic fairness and robustness for the local Saudi population? Don't let regulatory complexity slow your growth. At Pure Global, we combine local expertise with advanced AI tools to streamline your market access in Saudi Arabia and over 30 countries. We handle the entire lifecycle, from regulatory strategy and dossier submission to post-market surveillance. Get in touch with our experts to navigate the new SFDA landscape with confidence. Contact us at info@pureglobal.com or visit https://pureglobal.com/.
    Show More Show Less
    2 mins
  • Saudi Arabia's AI MedTech Rush: Pure Global on the SFDA's High-Stakes Fast-Track.

    Saudi Arabia's AI MedTech Rush: Pure Global on the SFDA's High-Stakes Fast-Track.
    Mar 31 2026
    This week, we dissect the groundbreaking 'Talaia' framework just launched by the Saudi Food & Drug Authority (SFDA). This new fast-track pathway promises to slash market entry times for AI-powered medical devices, opening up the lucrative Saudi market faster than ever before. But this speed comes at a price. We explore the critical shift from pre-market assessment to mandatory, intensive post-market surveillance. Learn what this new "approve now, verify later" model means for manufacturers, the new compliance burdens it creates, and how it is reshaping the regulatory landscape across the Middle East. **Case In Point:** Imagine your startup has a revolutionary AI diagnostic tool ready for the Saudi market. The old pathway meant a delay of over a year. The new 'Talaia' framework offers market access in just 90 days, but requires you to continuously collect and report real-world performance data from day one. Are your systems prepared for this new, intensive level of scrutiny? **Key Questions This Episode Answers:** - How does the SFDA's 'Talaia' framework redefine "market-ready" for AI devices? - What specific post-market surveillance data will you now be required to report? - Is your current Quality Management System equipped for continuous real-world performance monitoring? - How can you leverage this fast-track pathway without falling into hidden compliance traps? - What are the long-term implications for algorithm updates under this new rule? - Could this Saudi model become the new regulatory standard for the entire GCC? Navigating global markets requires a partner who understands the terrain. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We combine local expertise with advanced AI and data tools to streamline your market access, from initial strategy and technical dossier submission to continuous post-market surveillance. Let us help you turn regulatory challenges into market opportunities. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.
    Show More Show Less
    2 mins
  • Pure Global: Saudi MedTech's New Law - Cracking the SFDA's Code.

    Pure Global: Saudi MedTech's New Law - Cracking the SFDA's Code.
    Mar 30 2026
    This week on MENA MedTech Insights, we dissect the groundbreaking new product safety law proposed by the Saudi Food and Drug Authority (SFDA). This isn't just another update; it's a fundamental shift in how medical devices will be regulated in the Kingdom, placing a heavy emphasis on localized data and stricter compliance. We explore the specific changes that will impact your market access strategy, from new clinical evidence requirements for high-risk devices to the expanded responsibilities of local representatives. Learn what this means for your existing technical files and why your European or US data might not be enough anymore. For example, a European firm's launch of its advanced cardiac monitor in Saudi Arabia was abruptly halted. Despite having a valid CE mark, the SFDA demanded a new, local clinical study to validate its performance within the Saudi healthcare system, a request that added major delays and costs, putting their entire market strategy at risk. Key Takeaways This Episode: * What are the three biggest changes in the SFDA's proposed product safety law? * How will the new emphasis on local clinical data impact your registration timeline? * Is your current technical dossier truly prepared for the shift towards Saudi-specific requirements? * Why might your existing European clinical data no longer be sufficient for SFDA approval? * What is the critical new role your local representative must play in post-market surveillance? * How can you tell if your device classification is at risk of being changed under the new rules? * Are you prepared for the unannounced audits targeting compliance with the new regulations? Navigating complex regulatory shifts is our expertise at Pure Global. We offer end-to-end solutions, from developing a robust regulatory strategy and compiling technical dossiers with our AI tools to acting as your local representative in Saudi Arabia. We turn regulatory hurdles into market opportunities. Contact us at info@pureglobal.com or visit https://pureglobal.com to secure your presence in the evolving MENA market.
    Show More Show Less
    2 mins
No reviews yet